Journal Basic Info
- Impact Factor: 1.995**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
Major Scope
- Oral and Maxillofacial Surgery
- Surgical Oncology
- Transplant Surgery
- Gynecological Surgery
- Vascular Surgery
- Neurological Surgery
- Obstetrics Surgery
- Thoracic Surgery
Abstract
Citation: Clin Surg. 2022;7(1):3488.Review Article | Open Access
The Clinicopathologic Features and Management of Recurrent Thymoma
Jiahui Xu1, Xiaohui Ding2,3, Lifang Wang4 and Hongguang Zhao2,3*
1School of Clinical Medicine, Hangzhou Medical College, P.R. China
2Wenzhou Medical University, P.R. China
3Department of Thoracic Surgery, Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Cancer Hospital of the University of Chinese Academy of Science, P.R. China
4School of Innovation and Entrepreneurship, Hangzhou Medical College, P.R. China
*Correspondance to: Hongguang Zhao
PDF Full Text DOI: 10.25107/2474-1647.3488
Abstract
Thymoma is a relatively rare tumor. Thymoma can relapse after operation or radiochemotherapy. The definitions of recurrent thymoma have been made by ITMIG. It is necessary to find the risk factors for recurrence based on the clinicopathologic features. Masaoka stage, WHO histological type, tumor size and treatment modalities are all the risk factor of recurrent thymoma. The diagnosis of recurrence is very important for thymoma. Surgery is a main therapy for thymoma. Complete re-resection can achieve a better prognosis than non-surgical therapy or incomplete re-resection. Radiotherapy and chemotherapy are still the important non-surgical therapy. Other treatment, such as targeted therapy, immunotherapy and percutaneous cryoablation can be used in recurrent thymoma.
Keywords
Cite the article
Xu J, Ding X, Wang L, Zhao H. The Clinicopathologic Features and Management of Recurrent Thymoma. Clin Surg. 2022; 7: 3488..